Treatment of Crohn’s disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: a pilot study by K. W. A. Göttgens et al.
ORIGINAL ARTICLE
Treatment of Crohn’s disease-related high perianal fistulas
combining the mucosa advancement flap with platelet-rich
plasma: a pilot study
K. W. A. Go¨ttgens1 • R. R. Smeets1 • L. P. S. Stassen1 • G. L. Beets1 •
M. Pierik2 • S. O. Breukink1
Received: 16 December 2014 / Accepted: 18 April 2015 / Published online: 15 May 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Background Healing rates after surgical closure for high
perianal fistula in patients with Crohn’s disease are even
more disappointing than in patients with cryptoglandular
fistulas. The objective was to improve healing rates by
combining the well-known mucosal advancement flap with
platelet-rich plasma.
Methods A prospective pilot study was conducted in one
tertiary referral centre. Consecutive patients with primary
or recurrent Crohn’s disease-related high perianal fistulas,
defined as involving the middle and/or upper third parts of
the anal sphincter complex, were included. A staged pro-
cedure was performed with non-cutting seton treatment for
3 months first, followed by a mucosal advancement flap
with injection of platelet-rich plasma into the fistula tract.
Results Ten consecutive patients were operated on be-
tween 2009 and 2014. Half (50 %) of the patients had
undergone previous fistula surgery. Mean follow-up was
23.3 months (SD 13.0). Healing of the fistula was 70 %
(95 % confidence interval, 33–89 %) at 1 year. One (10 %)
patient had a recurrence, and in two (20 %) patients, the
fistula was persistent after treatment. An abscess occurred
in one (10 %) patient. The median post-operative Vaizey
score was 8.0 (range 0–21), indicating a moderate to severe
continence impairment.
Conclusions The results of combining the mucosal ad-
vancement flap with platelet-rich plasma in patients with
Crohn’s disease-related high perianal fistulas are moderate
with a healing rate of 70 %. Further investigation is needed
to determine the benefits and risks on continence status for
this technique in this patient population.
Keywords Mucosal advancement flap  Platelet-rich
plasma  High perianal fistula  Recurrence  Crohn’s
disease
Introduction
High perianal fistulas (HPFs) are difficult to treat, and
many techniques have been developed in recent years to
reduce recurrence rates and to maintain optimal post-op-
erative continence status [1–6]. Up to now, there is no
consensus regarding the best technique for the treatment of
this disease.
The high cryptoglandular perianal fistulas (HCPF) and
the Crohn’s disease-related high perianal fistulas (CDRF)
are the most common subtypes of HPF.
In a population-based cohort study, the cumulative fre-
quency of perianal Crohn’s disease (CD) complications was
12 %at 1 year, 15 %at 5 years, 21 %at 10 years and 26 %at
20 years, and other population-based studies report incidence
rates from 20 to 28 % [7–10]. According to the European
Crohn and Colitis Organisation (ECCO) guidelines for com-
plex perianal fistula, drainage of all abscesses, seton place-
ment anddilatationof strictures are recommendedfirst.Active
luminal disease should be treated. Thiopurines in combination
with antibiotics are the first medical choice [11]. Infliximab or
adalimumab should be used as a second-line medical treat-
ment [12–15]. Combining anti-tumour necrosis factor (TNF)
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treatment with ciprofloxacin may improve the outcome [16].
The recurrence rate of complex fistula after medical treatment
is high, and therefore, combination with surgery is recom-
mended. No surgery should be performed if active proctitis is
still present. Similar surgical techniques are used for both
HCPF and CDRF. However, healing rates are lower for
CDRF. For example, the mucosal advancement flap (MAF),
one of the most frequently used techniques, shows healing
rates of about 60–80 % for HCPF compared to only 40–50 %
for CDRF [17–20].
Other techniques for closure of CDRF show similar
disappointing results, with long-term healings rates of
around 55 % for fistula plugs [21], about 40 % for fibrin
glue [22] and about 33 % after ligation of the inter-
sphincteric fistula tract (LIFT) [23].
We have developed a technique in which the MAF is
combined with the injection of platelet-rich plasma (PRP)
into the fistula tract. PRP is hypothesized to improve
wound healing and might improve fistula closure of HPF.
Compared to fibrin glue, PRP in addition to clotting re-
leases many growth factors, which are not present in fibrin
glue. Long-term results using this technique for treatment
of HCPF were previously published and show favourable
results with healing of the fistula after 2 years of 83 %
(95 % confidence interval (CI) 62–93 %) [3]. We hy-
pothesized that the MAF in combination with PRP can also
improve the outcome of complex CDRF. To the best of our
knowledge, this treatment regimen has not been studied in
CD patients before. We therefore performed an open-label
prospective pilot study in primary and recurrent CDRF.
Materials and methods
Between November 2009 and March 2014, 10 consecutive
patients with primary or recurrent CDRF were included in
this pilot feasibility study. HPFs were defined as fistula in-
volving the middle and/or upper one-third of the anal
sphincter complex. Recto-vaginal fistulas were excluded.
Initial assessment of the fistula was done with clinical ex-
amination andmagnetic resonance imaging (MRI).MRIwas
used to confirm a HPF and to classify the route of the fistula
tract. Patients were only deemed fit for surgery if the luminal
CDwas in clinical and endoscopic (mucosal) remission after
medical treatment according to ECCO guidelines.
The first part of the surgical procedure included non-
cutting seton treatment for at least 3 months to reduce in-
flammation and drain sepsis, followed by a MAF with in-
jection of PRP in the fistula tract. Patients on
corticosteroids were first tapered off this medication. Pa-
tients with HPF of not due to CD were excluded, as well as
patients with bleeding disorders, local or haematological
malignancies and pregnant patients.
The primary outcomes of the study were healing and
recurrence rates of the CDRF. The secondary outcome was
continence status.
This study was conducted according to national medical
ethical laws and guidelines, and written informed consent
was obtained from all patients for the procedure and long-
term follow-up in the outpatient clinic. The local medical
ethics committee approved the study.
Procedure and preparation of PRP
The surgical procedure and preparation of PRP were pre-
viously described for treatment of HCPF and were not
changed for the treatment of CDRF in this study [3].
In short, patients were first treated with a non-cutting
seton for drainage of the fistula tract and treated with a
MAF combined with injection of PRP at least 3 months
after placement of the seton. The PRP was made from
55 mL of the patients’ own blood, resulting in PRP with a
6–8 times higher concentration of platelets compared to
baseline whole blood. A thrombin-coated syringe activated
the PRP during injection into the fistula tract. The
Gravitational Platelet Separation III (GPS-III) system in-
structions (Cell Factor Technologies, Biomet, Warsaw, IN,
USA) were used for the preparation of the PRP.
Follow-up
All patients were seen at the outpatient clinic for follow-up up
to 1 year post-operatively. Follow-up visits were at 6 weeks,
3 months, 6 months and 1 year after surgery. If needed, pa-
tients were invited in between these follow-up visits. Fistula
healing was defined as nomore symptoms, a macroscopically
closed external fistula opening and no drainage duringmanual
compression. In case of doubt about closure, anMRI scanwas
performed to visualize a possible fistula tract.At the end of the
study, patients who were not in clinical follow-up anymore
were contacted by phone to check whether the fistula was
closed. If this phone interview resulted in a suggestion of a
recurrent fistula, the patientwas invited to the outpatient clinic
for physical examination. At the end of follow-up, the Vaizey
score was used to evaluate continence status.
If the fistula was not closed 3 months after the op-
eration, it was considered a persisting fistula or treatment
failure. A new fistula occurring after a symptom-free pe-
riod was defined as a recurrence.
Results
Ten consecutive patients with CDRF were treated accord-
ing to protocol and were followed up prospectively. There
were three (30 %) males and seven (70 %) females.
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Median age was 47.5 years (range 30–67 years). Patient
characteristics with previous treatments and study out-
comes are shown in Tables 1 and 2. All patients were
treated with a seton for at least 3 months first before the
second operation was performed. All had a preoperative
MRI scan. Five (50 %) patients had recurrent fistula.
Eight (80 %) patients’ CDRF healed, with a median
healing time of 52.5 days (range 12–114 days), although
one (10 %) patient showed delayed healing with a time to
healing of 114 days (without any additional intervention).
One (10 %) of these healed patients developed a recurrence
44 days after complete closure of the fistula. The other two
(20 %) patients’ fistulas did not heal after the operation.
A Kaplan–Meier curve was created to show healing of
the fistulas (Fig. 1). Healing at 1 year was 70 % (95 % CI
33–89 %). Mean follow-up was 23.3 months (SD 13.0).
The patient with the recurrence was treated with a
MAF ? PRP again after another 3 months of seton treat-
ment and developed another recurrence. One of the patients
with a persisting fistula chose to have a colostomy and did
not want other treatment for the CDRF. This fistula closed
several months after colostomy placement. The other pa-
tient with a persisting fistula was treated with a
MAF ? PRP after another 3 months of seton treatment.
This fistula is still not closed to date.
An abscess occurred in one (10 %) patient post-op-
eratively. This was the patient with a persisting fistula, who
later received a colostomy. No other complications
occurred.
Seven (70 %) patients completed the Vaizey score
questionnaire 6 months post-operatively. Two of these
seven patients had a recurrence, and the others were all
healed. The median Vaizey score was 8 (range 0–21). No
preoperative data on continence status were available.
Discussion
We report data of the first study combining the MAF with
injection of PRP in the fistula tract for high CDRF. The
healing rate was moderate with a healing of the fistulas at
1 year of 70 % (95 % CI 33–89 %). The median Vaizey
score of 8.0 indicates a fairly severe impairment of conti-
nence status.
There were some limitations to this study. It was a small
single-centre prospective pilot study to evaluate the ef-
fectiveness of adding PRP to the MAF in this patient group.
Besides, data on preoperative continence status were not
available, making it difficult to determine influence of the
surgical procedure on continence status. Patients in follow-
up for more than 1 year were evaluated using telephone
interviews, which might have resulted in some bias in
results.
As previously explained [3], our surgical procedure is
based on the MAF, which is a well-known and much
performed operation for HPF. The rationale behind using
the MAF as the basis of our technique was to avoid long
learning curves for surgeons and to make results repro-
ducible. The results of our technique, as published previ-
ously, were promising for HCPF with healing at 2 years of
83 % (95 % CI 62–93 %) [3]. The results for the treatment
of CDRF are less favourable than hoped, although our
healing rates seem higher compared to the MAF alone [19,
20].
The reason for these less favourable results, compared to
the treatment of HCPF, is not clear. However, it is known
that the vascular endothelial growth factor (VEGF) re-
sponse is defective [24], and platelet-derived growth factor
(PDGF) might be responsible for maintenance of damaged
vasculature in patients with CD [25]. Both growth factors
have, respectively, a role in angiogenesis, and protein and
collagen synthesis and are released when using PRP as
described by van der Hagen et al. [26], thus improving
wound healing. This, however, might not be true for pa-
tients with CD. Furthermore, platelets in patients with in-
flammatory bowel disease show higher levels of some
interleukin receptors [27], which might change the effects
of PRP. The function of PRP, concerning wound healing,
in patients with CDRF might therefore be different. Un-
fortunately, no studies on the use of PRP in patients with
CD are available.
Table 1 Patient characteristics and results
Value
Male 3 (30 %)
Age 47.5 (30–67)
Smokers 4 (40 %)
BMI 25.7 (21.1–32.4)
Fistula location Extrasphincteric: 1 (10 %)
Intersphincteric: 2 (20 %)
Transsphincteric: 7 (70 %)
Previous operations None: 5 (50 %)
One operation: 0 (0 %)
Two operations: 1 (10 %)
[Two operations: 3 (30 %)
Unclear: 1 (10 %)
Recurrences 1 (10 %)
Persisting fistulas 2 (20 %)
Primary healing rate 7 (70 %)
Secondary healing rate 7 (70 %)
Values given as n (%) or as median (range)
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Regarding continence impairment, it is difficult to draw
conclusions. Our previous study in patients with HCPF did
not show much impairment of continence status. This study
in patients with CDRF resulted in a higher median Vaizey
score of 8.0, which would be classified as major inconti-
nence according to Dubsky et al. [28]. It is, however,
shown that the prevalence of faecal incontinence in patients
with CD is high, between 25 and 74 %, even without anal
fistula surgery [29]. This would make it even more im-
portant to clarify the influence of our surgical procedure
on, the perhaps already impaired, continence status of pa-
tients with CDRF.
Previous surgery, and specifically previous MAF, might
also have had a significant influence on continence status.
We use curettage for the fistula tract before performing the
MAF, and other surgeons use only mild abrasive de-ep-
ithelialization or even resect and core-out the tract. Since
all the previously treated patients were referred from others
centres, we are unsure what the influence of the prior
surgery was on their continence status.
Conclusions
The healing rate of CDRF treated using our technique is
70 % and favourable compared to the 40–50 % for the
MAF reported in other studies. Further investigation,
preferably as a randomized study, into the usefulness of
combining the MAF with PRP in patients with CDRF is
needed to see whether healing rates can actually be im-
proved, and especially to show the influence on continence
status post-operatively in a patient population with an al-
ready high risk of faecal incontinence.
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Table 2 Patient history and outcome




Previous fistula treatment Stoma Persisting
fistula
Recurrence
1 Mesalazine; azathioprine Primary – No No No
2 Adalimumab Primary – No No Yes
3 Azathioprine; infliximab Recurrent Fistulotomy; seton treatment No No No
4 Azathioprine; infliximab Recurrent Seton treatment (49) No No No
5 None Recurrent MAF, other treatments unknown No Yes No
6 Infliximab Recurrent Seton treatment (39), MAF ? stem cells No No No
7 Infliximab; 6-mercaptopurine Primary – No No No
8 Adalimumab Primary – No No No
9 Mesalazine; infliximab Primary – No Yes No
10 6-Mercaptopurine Recurrent Seton treatment (39), deviating
colostomy
Yes No No
MAF mucosal advancement flap
Fig. 1 Healing of the fistulas. Patients at risk: 0 months: 8; 5 months:
7; 10 months: 5; 15 months: 3; 20 months: 2; 25 months: 2
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